Oseltamavir

General

• Type: Antiviral - neuraminidase inhibitor
• Dosage Forms: capsule (30, 45, 75mg), powder for PO susp (6mg/mL)
• Common Trade Names: Tamiflu

Adult Dosing

Influenza

75mg PO BID x5d

Pediatric Dosing

5 day course

• 1-8 months: 3mg/kg PO BID
• 9-23 months: 3.5mg/kg PO BID
• 2-12 years:
  • <15kg: 30mg PO BID
  • 16-23kg: 45mg PO BID
  • 24-40kg: 60mg PO BID
  • >40kg: 75mg PO BID

Special Populations

• Pregnancy Rating: Category C
• Lactation: Unknown; caution required
• Renal Dosing
  • Adult
  • Pediatric
• Hepatic Dosing
  • Adult
  • Pediatric

Contraindications

• Allergy to class/drug

Adverse Reactions

Serious

Rare <1%

Arrhythmia, delirium, hemorrhagic colitis, hepatitis, seizure, TEN, SJS, angioedema, unstable angina, pseudomembranous colitis

Common

Abdominal pain, insomnia, nausea, vomitting, vertigo, epistaxis, ear complaints, conjunctivitis.

Pharmacology

• Half-life: 1-3 hrs (oseltamivir); 6-10hrs oseltamivir carboxylate)
• Metabolism: hepatic
• Excretion: urine/stool
• Mechanism of Action: competitive inhibition of influenza virus neuraminidase enzyme, effectively halting viral release from infected cells and passing through mucus membranes.

Authors:

Dac Teoli, Michael Holtz, Neil Young, Daniel Ostermayer, Ross Donaldson